Literature DB >> 32086289

Impairment in Baroreflex Sensitivity in Recent-Onset Type 2 Diabetes Without Progression Over 5 Years.

Jana-Luise Kück1, Gidon J Bönhof1,2,3, Alexander Strom1,2, Oana-Patricia Zaharia1,2, Karsten Müssig1,2,3, Julia Szendroedi1,2,3, Michael Roden1,2,3, Dan Ziegler.   

Abstract

Impaired baroreflex sensitivity (BRS) predicts cardiovascular mortality and is prevalent in long-term diabetes. We determined spontaneous BRS in recent-onset diabetes patients and its temporal sequence over 5 years by recording beat-to-beat blood pressure and R-R intervals over 10 minutes. Four time domain and four frequency domain BRS indices were computed in participants from the German Diabetes Study baseline cohort with recent-onset type 1/type 2 diabetes (n=206/381) and age-matched glucose-tolerant controls (Control 1/Control 2: n=65/83) and subsets of consecutive type 1/type 2 diabetes participants who reached the 5-year follow-up (n=84/137). Insulin sensitivity (M-value) was determined using a hyperinsulinemic-euglycemic clamp. After appropriate adjustment, three frequency domain BRS indices were reduced in type 2 diabetes compared to Control 2 and were positively associated with M-value and inversely associated with fasting glucose and HbA1c (P<0.05), whereas BRS was preserved in type 1 diabetes. After 5 years, a decrease in one and four BRS indices was observed in type 1 and type 2 diabetes patients, respectively (P<0.05), which was explained by the physiologic age-dependent decline. Unlike well-controlled recent-onset type 1 diabetes patients, those with type 2 diabetes show early baroreflex dysfunction, likely due to insulin resistance and hyperglycemia, albeit without progression over 5 years.
© 2020 by the American Diabetes Association.

Entities:  

Year:  2020        PMID: 32086289     DOI: 10.2337/db19-0990

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  6 in total

Review 1.  Cardiac Autonomic Neuropathy: A Progressive Consequence of Chronic Low-Grade Inflammation in Type 2 Diabetes and Related Metabolic Disorders.

Authors:  Nour-Mounira Z Bakkar; Haneen S Dwaib; Souha Fares; Ali H Eid; Yusra Al-Dhaheri; Ahmed F El-Yazbi
Journal:  Int J Mol Sci       Date:  2020-11-27       Impact factor: 5.923

Review 2.  Interplay between baroreflex sensitivity, obesity and related cardiometabolic risk factors (Review).

Authors:  Sofia K Konstantinidou; Georgia Argyrakopoulou; Nicholas Tentolouris; Vangelis Karalis; Alexander Kokkinos
Journal:  Exp Ther Med       Date:  2021-11-23       Impact factor: 2.447

3.  Physical Fitness and Cardiovascular Risk Factors in Novel Diabetes Subgroups.

Authors:  Nina Saatmann; Oana-Patricia Zaharia; Klaus Strassburger; Dominik Hans Pesta; Volker Burkart; Julia Szendroedi; Norbert Gerdes; Malte Kelm; Michael Roden
Journal:  J Clin Endocrinol Metab       Date:  2022-03-24       Impact factor: 5.958

4.  Metabolic Factors Predict Changes in Endothelial Function During the Early Course of Type 1 and Type 2 Diabetes.

Authors:  Oana Patricia Zaharia; Martin Schön; Luca Löffler; Klaus Strassburger; Clara Möser; Iryna Yurchenko; Kálmán Bódis; Sofia Antoniou; Yanislava Karusheva; Julia Szendroedi; Volker Burkart; Michael Roden
Journal:  J Clin Endocrinol Metab       Date:  2022-09-28       Impact factor: 6.134

5.  BOND study: a randomised double-blind, placebo-controlled trial over 12 months to assess the effects of benfotiamine on morphometric, neurophysiological and clinical measures in patients with type 2 diabetes with symptomatic polyneuropathy.

Authors:  Gidon J Bönhof; Gundega Sipola; Alexander Strom; Christian Herder; Klaus Strassburger; Birgit Knebel; Claudia Reule; Jan-Christoph Wollmann; Andrea Icks; Hadi Al-Hasani; Michael Roden; Oliver Kuss; Dan Ziegler
Journal:  BMJ Open       Date:  2022-02-03       Impact factor: 2.692

6.  High-intensity interval training for 12 weeks improves cardiovascular autonomic function but not somatosensory nerve function and structure in overweight men with type 2 diabetes.

Authors:  Gidon J Bönhof; Alexander Strom; Maria Apostolopoulou; Yanislava Karusheva; Theresia Sarabhai; Dominik Pesta; Michael Roden; Dan Ziegler
Journal:  Diabetologia       Date:  2022-03-11       Impact factor: 10.460

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.